{
  "@context": "aku-v2",
  "@type": "clinical-syndrome",
  "@id": "vasc:vasculitis:anca-associated",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:19:00.000Z",
    "updated": "2026-01-07T03:19:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vasculitis",
    "type": "vascular-disease",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "ANCA-Associated Vasculitis",
    "description": "Small vessel vasculitides associated with antineutrophil cytoplasmic antibodies",
    "key_concepts": [
      {
        "concept": "Disease Spectrum",
        "details": "GPA (Wegener's), MPA, EGPA (Churg-Strauss) constitute the main ANCA-associated vasculitides"
      },
      {
        "concept": "ANCA Specificity",
        "details": "PR3-ANCA associated with GPA; MPO-ANCA associated with MPA and EGPA"
      },
      {
        "concept": "Vascular Manifestations",
        "details": "Small vessel disease; renal (glomerulonephritis), pulmonary, peripheral nerve involvement"
      },
      {
        "concept": "Treatment",
        "details": "Rituximab or cyclophosphamide induction; maintenance with rituximab or azathioprine"
      }
    ],
    "clinical_significance": "ANCA testing is essential for diagnosis and prognosis"
  },
  "provenance": {
    "primary_sources": ["Kitching AR et al. Nat Rev Dis Primers 2020"]
  }
}
